Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment
Clinical trial NCT03132675 · UNKNOWN
Trial details
- NCT number
- NCT03132675
- Sponsor
- OncoSec Medical Incorporated
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-03
- Primary completion
- 2023-03-31
- Enrollment
- 143
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.